Patents by Inventor Michael Schraeml

Michael Schraeml has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160002346
    Abstract: The invention relates to anti-HER1 antigen binding proteins, e.g. anti-HER1 antibodies, that bind to the beta-hairpin of HER1, methods for selecting these antigen binding proteins, their preparation and use as medicament.
    Type: Application
    Filed: May 12, 2015
    Publication date: January 7, 2016
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Birgit Bossenmaier, Michael Gerg, Gerhard Niederfellner, Carmen Peess, Michael Schraeml
  • Publication number: 20160002338
    Abstract: The invention relates to specific anti-HER3 antibodies, that bind to the beta-hairpin of HER3, their preparation and use as medicament.
    Type: Application
    Filed: May 12, 2015
    Publication date: January 7, 2016
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Birgit Bossenmaier, Richard Buick, Michael Gerg, Frank Kroner, Gerhard Niederfellner, Carmen Peess, Michael Schraeml
  • Publication number: 20150175685
    Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.
    Type: Application
    Filed: December 18, 2014
    Publication date: June 25, 2015
    Inventors: Fiona Grueninger, Guy Georges, Olaf Mundigl, Michael Schraeml, Bernd Bohrmann, Ulrich Goepfert, Joerg Benz, Hubert Kettenberger
  • Publication number: 20140256915
    Abstract: The current invention is directed to the velocity factor. Based on the velocity factor antibodies can be classified, i.e. antibodies can be characterized on their binding properties as e.g. entropic or enthalpic antigen binder. A velocity factor based classification does not require detailed thermodynamic determinations and/or calculations. The velocity factor is the ratio of the antigen-antibody complex association rate constants ka determined at 37° C. and 13° C. As only two experimental determinations are required to calculate the velocity factor this is a fast and high-throughput suited method.
    Type: Application
    Filed: November 26, 2013
    Publication date: September 11, 2014
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Michael Schraeml, Leopold Von Proff
  • Publication number: 20140199782
    Abstract: The current invention reports a method for producing an antibody comprising the steps of a) providing a plurality of hybridoma cells each expressing an antibody, b) determining the time dependent amount of said antibody bound to the respective antigen by surface plasmon resonance at different temperatures and different antibody concentrations, c) calculating with the time dependent amount determined in b) based on equations (II) to (XIII) at least the thermodynamic parameters (i) standard association binding entropy (?S°‡ass), (ii) standard dissociation binding entropy (?S°‡diss), (iii) standard binding entropy (?S°), (iv) free standard binding enthalpy (?G°), (v) standard dissociation free binding enthalpy (?G°‡diss), (vi) standard association free binding enthalpy (?G°‡ass), (vii) ?T?S°, (viii) dissociation rate constant kd, (ix) equilibrium binding constant KD, and (x) association rate constant ka, d) selecting a hybridoma cell producing an antibody with at least two of the following: i) a standard associa
    Type: Application
    Filed: December 20, 2013
    Publication date: July 17, 2014
    Applicant: Hoffmann-La Roche Inc.
    Inventors: MICHAEL SCHRAEML, LEOPOLD VON PROFF
  • Publication number: 20140186354
    Abstract: The invention relates to anti-HER3/HER4 antigen binding proteins, e.g. anti-HER3/HER4 antibodies, that bind to the beta-hairpin of HER3 and the beta-hairpin of HER4, methods for selecting these antigen binding proteins, their preparation and use as medicament.
    Type: Application
    Filed: November 6, 2013
    Publication date: July 3, 2014
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Birgit Bossenmaier, Guy Georges, Michael Gerg, Gerhard Niederfellner, Christian Scholz, Michael Schraeml
  • Publication number: 20140186358
    Abstract: The invention relates to anti-HER3 antigen binding proteins, e.g. anti-HER3 antibodies, that bind to the beta-hairpin of HER3, methods for selecting these antigen binding proteins, their preparation and use as medicament.
    Type: Application
    Filed: November 6, 2013
    Publication date: July 3, 2014
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Birgit Bossenmaier, David Casagolda Vallribera, Guy Georges, Michael Gerg, Gerhard Niederfellner, Christian Scholz, Michael Schraeml
  • Publication number: 20140178393
    Abstract: Herein is reported a fusion polypeptide according to formula (I): NH2—S2—X1—S1—COOH, wherein X1 comprises either a random amino acid sequence or an amino acid sequence derived from a first polypeptide, S2 and S1 are non-overlapping amino acid sequences derived from a second polypeptide, and denotes a peptide bond, wherein the second polypeptide is a polypeptide with peptidyl-prolyl cis/trans-isomerase activity (PPIase activity) or is derived from the FKBP-fold domain family, wherein X1 is inserted in place of the insert-in-flap-domain of the second polypeptide.
    Type: Application
    Filed: May 4, 2012
    Publication date: June 26, 2014
    Inventors: Herbert Andres, David Casagolda Vallribera, Hartmut Duefel, Michael Gerg, Christian Scholz, Michael Schraeml
  • Publication number: 20140120561
    Abstract: Isolated antibodies that specifically bind to an epitope comprised in the stretch of amino acids ranging from amino acid 76 to amino acid 84 of human insulin-like growth factor-1 precursor (SEQ ID NO:1). Use of the novel antibodies for the sensitive and specific detection of insulin-like growth factor-1, in some embodiments while in the presence of high excess concentration of insulin-like growth factor-2, for example in a bodily fluid sample.
    Type: Application
    Filed: November 1, 2013
    Publication date: May 1, 2014
    Applicant: ROCHE DIAGNOSTICS OPERATIONS, INC.
    Inventors: Herbert Andres, Hartmut Duefel, Michael Gerg, Frank Kowalewsky, Christian Scholz, Michael Schraeml
  • Patent number: 8645083
    Abstract: The current invention reports a method for producing an antibody comprising the steps of a) providing a plurality of hybridoma cells each expressing an antibody, b) determining the time dependent amount of said antibody bound to the respective antigen by surface plasmon resonance at different temperatures and different antibody concentrations, c) calculating with the time dependent amount determined in b) based on equations (II) to (XIII) at least the thermodynamic parameters (i) standard association binding entropy formula (A), (ii) standard dissociation binding entropy formula (B), (iii) standard binding entropy (?S°), (iv) free standard binding enthalpy (?G°), (v) standard dissociation free binding enthalpy formula (C), (vi) standard association free binding enthalpy formula (D), (vii) ?T?S°, (viii) dissociation rate constant kd, (ix) equilibrium binding constant KD, and (x) association rate constant ka, d) selecting a hybridoma cell producing an antibody with at least two of the following: i) a standard a
    Type: Grant
    Filed: August 25, 2009
    Date of Patent: February 4, 2014
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Michael Schraeml, Leopold Von Proff
  • Patent number: 8617849
    Abstract: The current invention is directed to the velocity factor. Based on the velocity factor antibodies can be classified, i.e. antibodies can be characterized on their binding properties as e.g. entropic or enthalpic antigen binder. A velocity factor based classification does not require detailed thermodynamic determinations and/or calculations. The velocity factor is the ratio of the antigen-antibody complex association rate constants ka determined at 37° C. and 13° C. As only two experimental determinations are required to calculate the velocity factor this is a fast and high-throughput suited method.
    Type: Grant
    Filed: August 19, 2010
    Date of Patent: December 31, 2013
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Michael Schraeml, Leopold Von Proff
  • Publication number: 20130344094
    Abstract: Herein is reported a polypeptide-polynucleotide-complex as therapeutic agent and its use as tool for the targeted delivery of an effector moiety. The polynucleotide part of the complex is essentially resistant to proteolytic and enzymatic degradation in vivo. Additionally the polypeptide part specifically binds to a compound or structure such as a tissue or organ, a process or a disease. Thus, one aspect as reported herein is a polypeptide-polynucleotide-complex comprising a) a polypeptide specifically binding to a target and conjugated to a first member of a binding pair, b) a polynucleotide linker conjugated at its first terminus to the second member of the binding pair, and c) an effector moiety conjugated to a polynucleotide that is complementary to at least a part of the polynucleotide linker.
    Type: Application
    Filed: June 21, 2013
    Publication date: December 26, 2013
    Inventors: Michael Gerg, Dieter Heindl, Gerhard Niederfellner, Wolfgang Schaefer, Michael Schraeml, Michael Tacke
  • Patent number: 8609097
    Abstract: An antibody binding to Tau that is phosphorylated at serine 422 (pS422), which specifically binds to phosphorylated Tau fragment of SEQ ID NO:9 and to Tau pS422, but does not bind to Tau and to phosphorylated MCAK fragment of SEQ ID NO:17. The antibody is useful in the treatment of a Tauopathy.
    Type: Grant
    Filed: June 3, 2010
    Date of Patent: December 17, 2013
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bernd Bohrmann, Ulrich Goepfert, Fiona Grueninger, Walter Huber, Hans-Willi Krell, Valeria Lifke, Olaf Mundigl, Sonja Offner, Laurence Ozmen, Michael Schraeml
  • Patent number: 8592179
    Abstract: The present invention is directed to a method for the generation of binding proteins derived from the protein super-family of ubiquitin like proteins with modifications in their alpha helical region as well as to a protein obtainable by said method. Furthermore, the invention provides the use of a protein for the specific recognition, binding and neutralization of a predescribed target molecule, for the detection, quantitative determination, separation and/or for the isolation of a corresponding binding partner and the use of a protein of the invention, for diagnosis, prophylaxis and treatment of diseases in which the corresponding binding partner is directly or indirectly involved.
    Type: Grant
    Filed: November 15, 2007
    Date of Patent: November 26, 2013
    Assignee: Scil Proteins GmbH
    Inventors: Michael Schraeml, Erik Fiedler
  • Publication number: 20130288266
    Abstract: A bi-valent binding agent having a first monovalent binder that binds to a polypeptide epitope of a target polypeptide, a second monovalent binder that binds to a posttranslational polypeptide modification on the target polypeptide and a linker. Further disclosed are methods for the detection of a posttranslationally modified target polypeptide, for making the disclosed bi-valent binding agent, and for use of the disclosed bi-valent binding agent in histological staining procedures.
    Type: Application
    Filed: June 21, 2013
    Publication date: October 31, 2013
    Applicant: ROCHE DIAGNOSTICS OPERATIONS, INC.
    Inventors: Michael Gerg, Dieter Heindl, Christian Klein, Alfred Mertens, Volker Schmid, Michael Schraeml, Monika Soukupova, Michael Tacke
  • Publication number: 20130289251
    Abstract: A binding agent of the Formula A-a?:a-S-b:b?-B:X(n), wherein A as well as B is a monovalent binder, a?:a as well as b:b? is a binding pair wherein a? and a do not interfere with the binding of b to b? and vice versa, S is a spacer of at least 1 nm in length, :X denotes a functional moiety bound either covalently or via a binding pair to at least one of a?, a, b, b? or S, (n) is an integer and at least 1, - represents a covalent bond, and the linker a-S-b has a length of 6 to 100 nm. Also disclosed are methods of producing such binding agent and certain uses thereof.
    Type: Application
    Filed: June 21, 2013
    Publication date: October 31, 2013
    Inventors: Andreas Gallusser, Dieter Heindl, Michael Schraeml, Christoph Seidel, Herbert von der Eltz
  • Publication number: 20130288267
    Abstract: A bivalent binding agent, capable of binding a polypeptide dimer, consisting of two monovalent binders linked to each other via a linker, the first monovalent binder binds an epitope of a first target polypeptide comprised in said dimer and the second monovalent binder binds to an epitope of a second target polypeptide comprised in said dimer. Each monovalent binder has a Kdiss in the range of 5×10?3/sec to 10?4/sec, and the bivalent binding agent has a Kdiss of 3×10?5/sec or less. Methods of making and using such bivalent binding agent in histological staining procedures are also disclosed.
    Type: Application
    Filed: June 21, 2013
    Publication date: October 31, 2013
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Michael Gerg, Dieter Heindl, Alfred Mertens, Christoph Rutz, Michael Schraeml, Monika Soukupova, Claudio Sustmann, Michael Tacke, Jan van Dieck
  • Publication number: 20120156726
    Abstract: The current invention is directed to the velocity factor. Based on the velocity factor antibodies can be classified, i.e. antibodies can be characterized on their binding properties as e.g. entropic or enthalpic antigen binder. A velocity factor based classification does not require detailed thermodynamic determinations and/or calculations. The velocity factor is the ratio of the antigen-antibody complex association rate constants ka determined at 37° C. and 13° C. As only two experimental determinations are required to calculate the velocity factor this is a fast and high-throughput suited method.
    Type: Application
    Filed: August 19, 2010
    Publication date: June 21, 2012
    Inventors: Michael Schraeml, Leopold Von Proff
  • Publication number: 20110160436
    Abstract: The current invention reports a method for producing an antibody comprising the steps of a) providing a plurality of hybridoma cells each expressing an antibody, b) determining the time dependent amount of said antibody bound to the respective antigen by surface plasmon resonance at different temperatures and different antibody concentrations, c) calculating with the time dependent amount determined in b) based on equations (II) to (XIII) at least the thermodynamic parameters (i) standard association binding entropy formula (A), (ii) standard dissociation binding entropy formula (B), (iii) standard binding entropy (?S°), (iv) free standard binding enthalpy (?G°), (v) standard dissociation free binding enthalpy formula (C), (vi) standard association free binding enthalpy formula (D), (vii) ?T?S°, (viii) dissociation rate constant kd, (ix) equilibrium binding constant KD, and (x) association rate constant ka, d) selecting a hybridoma cell producing an antibody with at least two of the following: i) a standard a
    Type: Application
    Filed: August 25, 2009
    Publication date: June 30, 2011
    Inventors: Michael Schraeml, Leopold Von Proff
  • Publication number: 20110059093
    Abstract: An antibody binding to Tau that is phosphorylated at serine 422 (pS422), which specifically binds to phosphorylated Tau fragment of SEQ ID NO:9 and to Tau pS422, but does not bind to Tau and to phosphorylated MCAK fragment of SEQ ID NO:17. The antibody is useful in the treatment of a Tauopathy.
    Type: Application
    Filed: June 3, 2010
    Publication date: March 10, 2011
    Inventors: Bernd Bohrmann, Ulrich Goepfert, Fiona Grueninger, Walter Huber, Hans-Willi Krell, Valeria Lifke, Olaf Mundigl, Sonja Offner, Laurence Ozmen, Michael Schraeml